Carboxymethyl Dextran Coated Iron Oxide Magnetic Nanoparticles as Vehicles for CRISPR Ribonucleoproteins
Preprint
Abstract
The efficient and safe intracellular delivery of CRISPR ribonucleoproteins (RNPs) remains a major challenge for the development of genome editing strategies. Magnetic iron oxide nanoparticles (MNPs) offer an attractive and biocompatible delivery platform. However, their use for the delivery of functional CRISPR RNPs remains comparatively underexplored. Here, we developed carboxymethyl dextran (CMD)-coated MNPs as non-viral carriers for Cas9 and Cas12a RNPs. Nanocomplexes were formed through electrostatic interactions, without the need for chemical coupling reagents or additional surface functionalization. Both RNPs efficiently associated with MNPs, and the resulting nanocomplexes exhibited stable physicochemical properties and retained their cargo in serum-supplemented culture medium for up to 24 hours. Cellular uptake was confirmed by microscopy, while biocompatibility assays revealed no overt cytotoxicity. Functional genome editing was demonstrated at reporter and endogenous gene loci in HEK-293T cells, as well as in primary human dermal fibroblasts. Finally, we explored the therapeutic potential of this platform for recessive dystrophic epidermolysis bullosa (RDEB) by targeting COL7A1 exon 80, with the aim of removing the prevalent c.6527insC mutation while preserving the reading frame. Cas9 RNP nanocomplexes enabled exon 80 deletion. These findings establish CMD-coated MNPs as a versatile platform for the delivery of Cas9 and Cas12a RNPs and support further investigation of magnetic nanoparticle-mediated genome editing for inherited skin disorders.Keywords
Funding Information
- Ministerio de Ciencia, Innovacion y Universidades, Spain (PID2020-119352RB-I00)
- Ministerio de Ciencia, Innovacion y Universidades, Spain (PID2023-146982OB-I00)
- Comunidad de Madrid (PEJ-2023-AI/SAL-GL-27686)
This publication has 31 references indexed in Scilit:
- Viral and non-viral vectors in gene therapy: current state and clinical perspectivesEBioMedicine, 2025
- Gemcitabine and miRNA34a mimic codelivery with magnetic nanoparticles enhanced anti-tumor effect against pancreatic cancerJournal of Controlled Release, 2025
- Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2024
- Nanotechnology strategies to address challenges in topical and cellular delivery of siRNAs in skin disease therapyAdvanced Drug Delivery Reviews, 2024
- Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectorsMolecular Therapy - Methods & Clinical Development, 2022
- One-pot synthesis of carboxymethyl-dextran coated iron oxide nanoparticles (CION) for preclinical fMRI and MRA applicationsNeuroImage, 2021
- Recent advances in nanomaterials for therapy and diagnosis for atherosclerosisAdvanced Drug Delivery Reviews, 2021
- Cellular reprogramming with multigene activation by the delivery of CRISPR/dCas9 ribonucleoproteins via magnetic peptide-imprinted chitosan nanoparticlesMaterials Today Bio, 2021
- Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticlesAdvanced Drug Delivery Reviews, 2020
- The effect of surface charge of functionalized Fe3O4 nanoparticles on protein adsorption and cell uptakeBiomaterials, 2014